Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Frequently asked questions
What sector does Galapagos NV (GLPG) operate in?
Galapagos NV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Galapagos NV (GLPG) current stock price?
As of the latest data, Galapagos NV stock price is €26.80, with a previous close of €26.80.
What is Galapagos NV (GLPG) current market capitalization?
Galapagos NV market cap is approximately 1.77 billion.
What is Galapagos NV (GLPG) Earnings Per Share (EPS)?
The trailing EPS is €7.41, and the forward EPS is -€3.91.
What is Galapagos NV (GLPG) Price-to-Earnings (P/E) ratio?
Galapagos NV current P/E ratio is 3.62.
What is Galapagos NV (GLPG) EBITDA?
Galapagos NV EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -64.78 million.
Does Galapagos NV (GLPG) pay dividends?
No. Galapagos NV does not pay a dividend.
When is Galapagos NV (GLPG) next earnings report?
Galapagos NV is expected to release its next earnings report on March 31, 2026.
What is Galapagos NV (GLPG) beta (volatility) score?
Galapagos NV has a beta of 0.115, indicating lower volatility than the overall market.
